Leap zeroes in on subgroup for DKN-01, Keytruda combo

Shares of Leap tumbled Tuesday as investors digested updated data from the Phase I trial of DKN-01 that showed a lower response than reported in March for the mAb in combination with Keytruda for advanced gastroesophageal junction and gastric cancer. But the company is optimistic that the combination could provide a benefit for a biomarker-defined group of patients with poor prognosis.